ClinicalTrials.gg
Not yet recruitingNCT07634237SUPPRESS-HEUpdated Jun 8, 2026

Personalized Nutritional Intervention in Patients Undergoing TIPS Insertion for Refractory Ascites to Prevent Overt Hepatic Encephalopathy

An interventional study of High Energy and High Protein Diet 1 and High Energy and High Protein Diet 2 in Cirrhosis, Refractory Ascites and TIPS Insertion, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-08.

Primary conditionAscitesRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ascites
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Ascites.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study will evaluate whether a nutritional intervention is better than another to reduce the incidence of overt hepatic encephalopathy in patients undergoing TIPS insertion for refractory ascites.

02

Conditions studied

  • Cirrhosis
  • Refractory Ascites
  • TIPS Insertion

Browse trials for

Keywords

  • Personalized Nutritional Intervention
  • Overt Hepatic Encephalopathy
  • Cirrhosis
  • Refractory Ascites
  • TIPS Insertion
03

In context

Ascites Reclassified

247 studies on the registry are indexed under Ascites; 57 are open to participants now.

This study's planned enrollment of 50 is close to the median of 54 across 179 interventional studies indexed under Ascites.

Browse Ascites studies →

Lead sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 421 studies on the registry; 105 are open to participants now.

Compared within Ascites, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of cirrhosis
  • TIPS planned for ascites
  • Being at least moderately malnourished

Exclusion criteria

Exclusion Criteria:

  • TIPS insertion for other reason than ascites
  • Budd Chiari Syndrome
  • Complete or cavernomatous portal vein thrombosis
  • Pre-TIPS recurrent or persistent overt hepatic encephalopathy
  • Use of lactulose or rifaximin in the last 4 weeks
  • Liver failure (MELD > 18 or score > 12)
  • Heart failure ( ≥ III or \< 50%)
  • Kidney failure (serum creatinine > 250µmol/L)
  • Pregnancy or breastfeeding
  • Previous Liver transplantation
  • Unable to provide
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Nutrition Intervention 1

    As participants are blinded, description of the arm is meant to maintain the blinding. Participants will meet the study dietitian who will perform a nutritional assessment. The study dietitian will then prescribe a high-energy and high-protein diet with or without the use of oral nutritional supplements that will fit your taste preferences and dietary needs. The nutritional intervention will focus on having 3 meals per day and 3 snacks per day, including at bedtime.

    Dietary Supplement: High Energy and High Protein Diet 1

  • Active comparator
    Nutrition Intervention 2

    As participants are blinded, description of the arm is meant to maintain the blinding. Participants will meet the study dietitian who will perform a nutritional assessment. The study dietitian will then prescribe a high-energy and high-protein diet with or without the use of oral nutritional supplements that will fit your taste preferences and dietary needs. The nutritional intervention will focus on having 3 meals per day and 3 snacks per day, including at bedtime.

    Dietary Supplement: High Energy and High Protein Diet 2

Interventions

  • Dietary supplementHigh Energy and High Protein Diet 1

    As participants are blinded, description of the intervention is meant to maintain the blinding. Participants will meet the study dietitian who will perform a nutritional assessment. The study dietitian will then prescribe a high-energy and high-protein diet with or without the use of oral nutritional supplements that will fit your taste preferences and dietary needs. The nutritional intervention will focus on having 3 meals per day and 3 snacks per day, including at bedtime.

  • Dietary supplementHigh Energy and High Protein Diet 2

    As participants are blinded, description of the intervention is meant to maintain the blinding. Participants will meet the study dietitian who will perform a nutritional assessment. The study dietitian will then prescribe a high-energy and high-protein diet with or without the use of oral nutritional supplements that will fit your taste preferences and dietary needs. The nutritional intervention will focus on having 3 meals per day and 3 snacks per day, including at bedtime.

06

What researchers measure

Primary outcomes

  1. Incidence of overt hepatic encephalopathy

    Time frame: 6 months

Secondary outcomes

  1. Changes in nutritional status using the PG-SGA scale

    Time frame: 6 months

  2. Changes in brain function using the Stroop Test (EncephalApp)

    Time frame: 6 months

  3. Changes in frailty using the Liver Frailty Index

    Time frame: 6 months

  4. Changes in patient-reported outcomes using Chronic Liver Disease Questionnaire

    Time frame: 6 months

Other outcomes

  1. Feasibility outcomes including recruitment rate and study completion

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2029, 36 months later.

Of 33 interventional studies with no phase under Ascites, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 62. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Jun 8, 2026
StartEst.
Jun 15, 2026
Primary completionEst.
Jun 15, 2029
CompletionEst.
Dec 15, 2029
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07634237
Collaborators
Canadian Institutes of Health Research (CIHR)
Responsible party
Amine Benmassaoud (Principal Investigator, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Jun 8, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Jun 15, 2029 (estimated)
Completion
Dec 15, 2029 (estimated)
Last update
Jun 8, 2026

Study contacts

Nassim Oumansour, BSc
Contact
nassim.oumansour@rimuhc.ca
514-934-1934 ext. 34868
Amine Benmassaoud, MD
principal investigator · Research Institute of the McGill University Health Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion